Skip to content
Inciteful Med
Resources About us Ask a Question

Will I Need Radiation After SFT Surgery? | Inciteful Med

Published: | Updated:

For many solitary fibrous tumor (SFT) patients, surgery is the only treatment needed. However, doctors may recommend adjuvant radiation therapy if tumor cells remain at the surgical margins, the tumor has aggressive features, or it is located in the brain or spine.

Key Takeaways

  • • Surgery alone is often sufficient for completely removed, low-risk solitary fibrous tumors.
  • • Adjuvant radiation therapy is frequently recommended if microscopic tumor cells are left at the surgical margins (an R1 or R2 resection).
  • • Tumors with aggressive biological features, such as a high Demicco score, may require radiation to prevent the tumor from growing back at the original site.
  • • SFTs located in the central nervous system (brain and spine) have a higher risk of local recurrence, making radiation a common part of treatment.
  • • Lifelong surveillance with CT or MRI scans is essential for all SFT patients due to the risk of the tumor returning years later.

For many people with a solitary fibrous tumor (SFT), surgery is the only treatment needed. Adjuvant radiation therapy (radiation given after surgery) is not a universal requirement [1][2]. However, your doctors will strongly consider radiation if the tumor was difficult to completely remove, if it has aggressive biological features, or if it was located in the brain or spine [2][3].

(Note: The numbers in brackets [ ] refer to citations from peer-reviewed medical literature used to support the facts in this guide.)

Why Radiation Might Be Recommended

Following surgery, your medical team will review the pathology report to determine if radiation is needed to prevent local recurrence (the tumor growing back in the exact same spot). The decision typically depends on three main factors:

  • Surgical Margins: The goal of surgery is to achieve negative margins (or an R0 resection), meaning a rim of healthy tissue was removed along with the tumor to ensure no cells were left behind [4][5]. If the pathology report shows tumor cells at the very edge of the removed tissue (positive margins, or an R1/R2 resection), it means microscopic tumor cells may remain in your body. In these cases, adjuvant radiation is frequently recommended to destroy those remaining cells and improve local control [6][2].
  • Your Demicco Risk Score: For SFTs found outside the brain and spine, doctors often use a risk stratification tool like the Demicco score [7][8]. This score evaluates your age, the size of the tumor, how fast the cells are dividing (mitotic rate), and if there are areas of dead tumor cells (necrosis) [7][9]. It is important to note that the Demicco score primarily predicts the risk of the tumor spreading to other parts of the body (distant metastasis) [7]. Radiation does not prevent distant metastasis—it only treats the surgical site. However, if your tumor has aggressive features (like a high mitotic rate), doctors may favor aggressive local control with radiation to ensure the tumor doesn’t grow back at the original site [10][11]. For low-risk tumors that were completely removed, surgery alone is usually sufficient [1].
  • Tumor Location (Brain and Spine): SFTs located in the central nervous system (CNS) behave differently and have a higher tendency to grow back locally [3][12]. Because of this, adjuvant radiation is frequently utilized for intracranial (brain) and spinal SFTs [3][6]. Research supports using radiation to improve disease control in the CNS, sometimes even when the surgeon was able to completely remove the tumor [13][14].

The Decision-Making Process

Because the role of radiation therapy for extra-CNS (soft tissue or lung/pleural) SFTs is not completely standardized in universal medical guidelines, the decision is highly individualized [15][2]. Your case will likely be reviewed by a multidisciplinary tumor board—a team of specialists including surgeons, medical oncologists, and radiation oncologists.

They will weigh the benefits of preventing a local recurrence against the potential side effects of radiation based on your tumor’s specific location [2][16]. Side effects vary widely depending on the area being treated but commonly include fatigue and localized skin irritation (similar to a sunburn) over the treatment area.

If recommended, the logistics of your treatment will depend on the tumor’s location:

  • For tumors in the body: You might receive External Beam Radiation Therapy (EBRT), which is typically given in brief, daily outpatient sessions over a period of several weeks.
  • For brain or spine tumors: Specialized, highly targeted radiation like Stereotactic Radiosurgery (SRS) might be used, which is often completed in a much shorter timeframe (sometimes a single session to a few sessions) [3][17].

Long-Term Monitoring

Whether you receive radiation therapy or not, SFTs have a known potential to return locally or spread to other parts of the body years—or even decades—later [18][12]. Because of this risk of “late recurrence,” long-term—and often lifelong—surveillance is universally recommended [19].

Your team will likely schedule regular imaging, such as CT or MRI scans [19][20]. This typically starts with scans every few months for the first few years, eventually spacing out to once a year, to ensure any changes are caught as early as possible.

Frequently Asked Questions

Do all SFT patients need radiation after surgery?
No, for many people, surgery is the only treatment needed. Radiation is generally recommended if the tumor was difficult to completely remove, has aggressive biological features, or is located in the brain or spine.
What are surgical margins and why do they matter for SFT?
Surgical margins refer to the edge of the tissue removed during surgery. If tumor cells are found at this edge (positive margins), radiation is frequently recommended to destroy remaining microscopic cells and prevent the tumor from growing back.
What does a Demicco score mean for my SFT treatment?
The Demicco score evaluates factors like your age, tumor size, and cell division rate to predict how aggressive the tumor is. If your score indicates aggressive features, doctors may recommend radiation to help ensure the tumor does not return at the surgical site.
Why is radiation more common for SFTs in the brain or spine?
Solitary fibrous tumors located in the central nervous system have a higher tendency to grow back in the same spot. Because of this, specialized radiation is frequently used to improve disease control even if the surgeon was able to completely remove the tumor.
Will I still need scans if my SFT was completely removed?
Because solitary fibrous tumors have the potential to return locally or spread to other parts of the body years or even decades later, long-term surveillance with regular CT or MRI scans is universally recommended.

Questions for Your Doctor

  • • What were the final surgical margins on my pathology report (R0, R1, or R2)?
  • • What is my Demicco risk score, and how does that impact the decision for or against radiation?
  • • Has my case been reviewed by a multidisciplinary tumor board to discuss adjuvant therapies?
  • • If radiation is recommended, what specific type (e.g., EBRT, SRS) will I receive, and what will the daily schedule look like?
  • • What are the anticipated short-term and long-term side effects of radiation based on the specific location of my tumor?
  • • What will my long-term surveillance plan look like in terms of scan frequency and type (CT vs. MRI)?

Questions for You

  • • How do I feel about the possibility of the tumor returning, and does that make me lean toward or against further treatment if it is offered as an option?
  • • If daily radiation therapy is recommended for several weeks, do I have the logistical support and transportation needed to attend those appointments?
  • • Are there lifestyle factors or other health conditions I have that might make dealing with the side effects of radiation particularly challenging?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Retroperitoneal solitary fibrous tumor: surgery as first line therapy.

    Rajeev R, Patel M, Jayakrishnan TT, et al.

    Clinical sarcoma research 2015; (5()):19 doi:10.1186/s13569-015-0034-y.

    PMID: 26322223
  2. 2

    Solitary fibrous tumor/hemangiopericytoma of the cervical spine: A systematic review of the literature with an illustrative case.

    Colamaria A, Carbone F, Sacco M, et al.

    Surgical neurology international 2022; (13()):532 doi:10.25259/SNI_722_2022.

    PMID: 36447863
  3. 3

    Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients.

    Li Q, Deng W, Sun P

    World neurosurgery 2022; (166()):e60-e69 doi:10.1016/j.wneu.2022.06.089.

    PMID: 35760325
  4. 4

    Hybrid Management of Giant Solitary Intracranial Fibrous Tumors: A Report of Two Cases.

    Alvis Peña DJ, Morales Baez JA, Espinosa Lira F, et al.

    Cureus 2025; (17(7)):e87798 doi:10.7759/cureus.87798.

    PMID: 40799885
  5. 5

    Solitary Fibrous Tumor/Hemangiopericytoma of Spinal Cord: A Retrospective Single-Center Study of 16 Cases.

    Wang J, Zhao K, Han L, et al.

    World neurosurgery 2019; (123()):e629-e638 doi:10.1016/j.wneu.2018.12.004.

    PMID: 30554000
  6. 6

    Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study.

    Kinslow CJ, Bruce SS, Rae AI, et al.

    Journal of neuro-oncology 2018; (138(1)):173-182 doi:10.1007/s11060-018-2787-7.

    PMID: 29427152
  7. 7

    Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

    Demicco EG, Wagner MJ, Maki RG, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(10)):1433-1442 doi:10.1038/modpathol.2017.54.

    PMID: 28731041
  8. 8

    Solitary Fibrous Tumors of the Female Genital Tract: A Study of 27 Cases Emphasizing Nonvulvar Locations, Variant Histology, and Prognostic Factors.

    Devins KM, Young RH, Croce S, et al.

    The American journal of surgical pathology 2022; (46(3)):363-375 doi:10.1097/PAS.0000000000001829.

    PMID: 34739418
  9. 9

    A Rare Case of Solitary Fibrous Tumor Involving the Nasolacrimal Duct System in a 12-Year-Old Female: A Case Report and Review of the Literature.

    Sheth NT, Adetunji MO, Smith ET, et al.

    Ophthalmic plastic and reconstructive surgery 2025; (41(3)):e89-e95 doi:10.1097/IOP.0000000000002854.

    PMID: 39700394
  10. 10

    Hemangiopericytoma/Solitary Fibrous Tumor in the central nervous system. Experience with surgery and radiotherapy as a complementary treatment: A 10-year analysis of a heterogeneous series in a single tertiary center.

    González-Vargas PM, Thenier-Villa JL, Sanromán Álvarez P, et al.

    Neurocirugia 2020; (31(1)):14-23 doi:10.1016/j.neucir.2019.06.001.

    PMID: 31351895
  11. 11

    The Third-Time Recurrence of a Thoracic Solitary Fibrous Tumor in a Patient Presenting With Paraneoplastic Hypoinsulinemic Hypoglycemia (Doege-Potter Syndrome).

    Zakar R, Saad N, Nehme K, et al.

    Cureus 2024; (16(5)):e60256 doi:10.7759/cureus.60256.

    PMID: 38746482
  12. 12

    Intracranial Solitary Fibrous Tumor/Hemangiopericytoma Treated with Microsurgical Resection: Retrospective Cohort Analysis of a Single-Center Experience.

    Swaminathan S, Ruzevick J, Venur V, et al.

    Therapeutics and clinical risk management 2022; (18()):901-912 doi:10.2147/TCRM.S375064.

    PMID: 36092453
  13. 13

    The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11).

    Lee JH, Jeon SH, Park CK, et al.

    Cancer research and treatment 2022; (54(1)):65-74 doi:10.4143/crt.2021.142.

    PMID: 33781051
  14. 14

    Clinical outcomes in central nervous system solitary-fibrous tumor/hemangiopericytoma: a STROBE-compliant single-center analysis.

    Yu Y, Hu Y, Lv L, et al.

    World journal of surgical oncology 2022; (20(1)):149 doi:10.1186/s12957-022-02619-w.

    PMID: 35538540
  15. 15

    High-cervical solitary fibrous tumour-a case report, and mini-bibliometric analysis.

    Liew YY, Abbou Z, Mbadugha T, Karmi Z

    Journal of surgical case reports 2025; (2025(7)):rjaf492 doi:10.1093/jscr/rjaf492.

    PMID: 40656152
  16. 16

    Diagnosis and treatment of solitary fibrous tumor/hemangiopericytoma of central nervous system. Retrospective report of 17 patients and literature review.

    Ma L, Wang L, Fang X, et al.

    Neuro endocrinology letters 2018; (39(2)):88-94.

    PMID: 30183202
  17. 17

    Successful multimodal management of central nervous system solitary fibrous tumor: A case report.

    Mjabber RE, Chahid M, Alami R, et al.

    Radiology case reports 2025; (20(1)):51-58 doi:10.1016/j.radcr.2024.09.105.

    PMID: 39429707
  18. 18

    Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature.

    Lavacchi D, Antonuzzo L, Briganti V, et al.

    Anti-cancer drugs 2020; (31(6)):646-651 doi:10.1097/CAD.0000000000000900.

    PMID: 31972591
  19. 19

    Solitary Fibrous Tumors of the Head and Neck: A Single-Institution Study of 52 Patients.

    Chung HR, Tam K, Han AY, et al.

    OTO open 2022; (6(3)):2473974X221098709 doi:10.1177/2473974X221098709.

    PMID: 35845143
  20. 20

    Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

    Sagiv O, Bell D, Guo Y, et al.

    Ophthalmic plastic and reconstructive surgery 2019; (35(2)):148-154 doi:10.1097/IOP.0000000000001189.

    PMID: 30371551

This page provides educational information about post-surgery radiation for solitary fibrous tumors. Always consult your multidisciplinary tumor board, including your surgical and radiation oncologists, to determine the best treatment plan for your specific case.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.